Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

AMP 511

 

Design:
An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.


Eligibility:
Subjects who meet the following criteria may be eligible for study participation:

  1. Diagnosis of Chronic Fatigue Syndrome ( 12 months) as defined by the 1988 CDC case definition of CFS

  2. Adults ages 18 to 65 years of age

  3. Karnofsky Performance Score from 20 to 60 during baseline

Status:
The study is open to enrollment

Locations:
 
Charlotte, NC
Incline Village, NV
Salt Lake City, UT


Please contact Hemispherx Biopharma for additional information regarding trial locations and site contacts:

  

By Fax: 215-988-1739
By E-Mail: trialinfo@hemispherx.net
By Mail: Hemispherx Biopharma, Inc.
One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia, PA 19103